Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Tyson Foods, Inc. — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $69 (market cap $30.93B), while Tyson Foods, Inc. trades at $54.86 (market cap $19.07B). The key difference: GE HealthCare Technologies Inc. Common Stock is the larger of the two by market cap, and Tyson Foods, Inc. pays the higher dividend (3.76%). Which is the better fit depends on your goals.
| GEHC | TSN | |
|---|---|---|
Market Cap | $30.93B | $19.07B |
Volume | 5,033,451 | 3,837,889 |
Sector | Health | Consumer Staples |
52-Week High | $88.16 | $68.75 |
52-Week Low | $59.48 | $50.47 |
Enterprise Value | $39.39B | $26.34B |
Dividend Yield | 0.23% | 3.76% |
Typical Hold Time | — | 77 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Tyson Foods (TSN) trades at $53.79, up 0.41% with a bullish technical signal despite recent volatility. The company shows mixed fundamentals with a P/E of 33.2 and thin 1.03% net margin, though revenue grew to $54.44B in 2025. Recent earnings beat expectations in Q1 and Q2 2026, but the stock faces headwinds from beef segment losses and a securities investigation.
Outlook remains cautious with analyst consensus at Buy (53%) and a $65.40 price target offering 22% upside. Key risks include ongoing beef losses, margin pressure, and legal scrutiny. The dividend appears sustainable with consistent payments, but investor confidence hinges on operational turnaround and Q4 earnings results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
